Comparing chemoradiation and surgery for advanced esophageal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to compare the outcomes of two treatment approaches for Chinese patients with locally advanced resectable esophageal squamous cell cancer. Patients will be randomly assigned to receive either definitive chemoradiation (CRT) or standard esophagectomy. The CRT group will undergo intensity-modulated radiation therapy combined with chemotherapy, while the surgery group will receive the standard surgical procedure. The study will follow patients for five years to assess disease-free survival and overall survival rates, as well as treatment-related adverse events and quality of life.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Chinese
* esophageal squamous cell cancer
* mid or lower esophageal cancer
* tumor is resectable disease
* clinical stage: cT1bN+Mo, or cT2-4aN0-2M0

Exclusion Criteria:

* who had distant metastasis to solid visceral organs or local invasion into trachea, descending aorta, or recurrent laryngeal nerve.
* who had a serious premorbid condition or a poor physical status that compromised a thoracotomy.

Where it's running

• Anyang Tumor Hospital
  Anyang, Henan, China Recruiting
• The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology
  Luoyang, Henan, China Recruiting

Study contacts

• Principal investigator: Ruinuo Jia, MD — The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology
• Study coordinator: Shegan Gao, MD, PhD
• Email: gsg112258@163.com
• Phone: +86 18638859977

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Personalized Ultrafractionated Stereotactic Radiotherapy with Perioperative FLOT for GEJ and Esophageal Cancer

  This trial tests adding a personalized, ultra-fractionated radiotherapy boost (PULSAR) to standard perioperative FLOT chemotherapy for patients with esophageal or gastroesophageal junction cancer to see if it can be used safely.

  Recruiting Phase 1 University of Texas Southwestern Medical Center · Dallas, Texas · NCT07700420

• Preventing nausea and vomiting during multi-cycle chemo and immunotherapy in esophageal and lung cancer

  This study tests a combination antiemetic with dexamethasone to see if it lowers nausea and vomiting in adults with esophageal or lung cancer receiving several cycles of chemo plus immunotherapy.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07617246

• Ivonescimab plus FOLFOX for advanced HER2-negative stomach and gastroesophageal junction adenocarcinoma

  This study tests whether adding ivonescimab to standard FOLFOX chemotherapy helps people with advanced, HER2-negative stomach or gastroesophageal junction adenocarcinoma as first-line treatment.

  Recruiting at 2 sites Phase 2 Massachusetts General Hospital · Santa Monica, California and 1 other locations · NCT07070466

• AI prediction of response to pre-surgery chemoimmunotherapy for esophageal cancer

  This project tests whether combining clinical records, CT scans, pathology, and lab results with deep learning can predict which patients with locally advanced esophageal cancer will respond to neoadjuvant chemoimmunotherapy before surgery.

  Recruiting Central South University · Changsha, Hunan · NCT07063901

• 18F-G1 PET/CT to see early immunotherapy response in solid tumors and blood cancers

  We are testing if the 18F-G1 PET/CT scan can help tell early on whether people with solid tumors or blood cancers will respond to immunotherapy.

  Recruiting Peking University First Hospital · Beijing · NCT07039474

• Combining afatinib and palbociclib for previously treated advanced esophageal squamous cell carcinoma

  This trial tests whether taking afatinib together with palbociclib helps control tumor growth in people with recurrent or metastatic esophageal squamous cell carcinoma who have already received prior treatments.

  Recruiting Phase 1/2 West China Hospital · Chengdu, Sichuan · NCT06753747

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.